6.52
0.04 (0.62%)
| Previous Close | 6.48 |
| Open | 6.50 |
| Volume | 595,283 |
| Avg. Volume (3M) | 1,102,570 |
| Market Cap | 408,286,976 |
| Price / Sales | 7.61 |
| Price / Book | 1.48 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2025 - 4 Aug 2025 |
| Operating Margin (TTM) | -476.01% |
| Diluted EPS (TTM) | -5.80 |
| Quarterly Revenue Growth (YOY) | 78.00% |
| Total Debt/Equity (MRQ) | 2.89% |
| Current Ratio (MRQ) | 9.13 |
| Operating Cash Flow (TTM) | -311.09 M |
| Levered Free Cash Flow (TTM) | -179.04 M |
| Return on Assets (TTM) | -36.35% |
| Return on Equity (TTM) | -63.53% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Sage Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.0 |
| Average | 0.63 |
|
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.41% |
| % Held by Institutions | 83.79% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |